WILSON TROY EDWARD sold $78K of PBYI
WILSON TROY EDWARD sold 10,800 shares of PUMA BIOTECHNOLOGY, INC. (PBYI) at $7.20 on 2026-06-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale by a director, including trade size, price, and post-transaction holdings, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor insider activity for sentiment, but this disclosure alone does not introduce new fundamentals.
What to watch
The filing does not state reasons for the sale, and it provides no accompanying changes in business outlook, guidance, or risk factors.
Background
The article is an SEC Form 4 insider transaction disclosure for PUMA Biotechnology, Inc. (PBYI).
Ticker impact
PBYI director Wilson Troy Edward sold 10,800 shares in an open-market transaction at $7.1989 on 2026-06-12 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.
The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, and the article provides no new operational, financial, or regulatory catalyst for PBYI.
Market effects
No clear sector read-through; this is company-specific insider trading data.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerPUMA BIOTECHNOLOGY, INC.
Company whose director insider sale is disclosed via SEC Form 4.
- insiderWILSON TROY EDWARD
Director who sold 10,800 shares at $7.1989/share on 2026-06-12 under a 10b5-1 plan.
